HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW)

Key Points

• HC Wainwright raised Harrow’s Q4 2027 EPS forecast to $1.07 from $1.06, while the consensus estimate for the current full year is $0.29 per share.
• Harrow’s latest quarterly results missed expectations, reporting a loss of $0.46 per share versus the projected loss of $0.18, though revenue of $70.66 million exceeded estimates of $69.84 million.
• Analyst sentiment remains mixed but leans positive: eight analysts rate Harrow a Buy, one rates it Hold and two rate it Sell, producing a “Moderate Buy” consensus and an average price target of $69.43.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at HC Wainwright raised their Q4 2027 earnings per share (EPS) estimates for shares of Harrow in a report released on Wednesday, August 12th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of $1.07 for the quarter, up from their previous forecast of $1.06. The consensus estimate for Harrow's current full-year earnings is $0.29 per share.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.28). The business had revenue of $70.66 million for the quarter, compared to analysts' expectations of $69.84 million. Harrow had a negative return on equity of 31.83% and a negative net margin of 13.51%.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Harrow from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. BTIG Research restated a "buy" rating and set a $63.00 price objective on shares of Harrow in a research report on Tuesday. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Harrow in a report on Monday, July 20th. Cantor Fitzgerald cut their target price on shares of Harrow from $91.00 to $88.00 and set an "overweight" rating for the company in a research report on Wednesday, May 13th. Finally, Zacks Research downgraded Harrow from a "hold" rating to a "strong sell" rating in a research report on Tuesday. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $69.43.

Harrow Trading Down 0.2%

Shares of HROW opened at $39.36 on Thursday. The firm's 50 day simple moving average is $40.72 and its 200 day simple moving average is $39.92. The company has a market capitalization of $1.48 billion, a P/E ratio of -39.36 and a beta of 0.28. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.30. Harrow has a 1-year low of $28.54 and a 1-year high of $54.85.

Insider Activity at Harrow

In other Harrow news, Director Adrienne L. Graves bought 1,000 shares of the firm's stock in a transaction that occurred on Monday, May 18th. The shares were bought at an average price of $31.07 per share, for a total transaction of $31,070.00. Following the transaction, the director directly owned 1,000 shares in the company, valued at $31,070. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.80% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HROW. Larson Financial Group LLC boosted its holdings in Harrow by 13.1% during the 4th quarter. Larson Financial Group LLC now owns 2,446 shares of the company's stock valued at $120,000 after acquiring an additional 284 shares during the period. The Manufacturers Life Insurance Company increased its stake in Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company's stock worth $505,000 after purchasing an additional 341 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company's stock worth $88,000 after purchasing an additional 369 shares during the period. Captrust Financial Advisors lifted its position in Harrow by 0.5% in the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company's stock valued at $3,428,000 after purchasing an additional 376 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company's stock valued at $1,422,000 after purchasing an additional 500 shares during the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

About Harrow

Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source